Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure

• Published in: Quality of life research 2012-02, Vol.21 (1), p.143-153
• Main Authors: Chatzikyriakou, Sofia V., Tziakas, Dimitrios N., Chalikias, Georgios K., Stakos, Dimitrios, Papazoglou, Dimitrios, Lantzouraki, Asimina, Thomaidi, Adina, Boudoulas, Harisios, Konstantinides, Stavros
• Format: Article
• Language: English
• Subjects: Aged; Biomarkers; Biomarkers - blood; Cardiology; Cardiomyopathy; Cardiovascular disease; CLINICAL AND POLICY APPLICATIONS; Collagen; Collagen - metabolism; Collagen Type I - blood; Collagens; Congestive heart failure; Consent; Etiology; Female; Fibrosis; Health Status; Heart; Heart failure; Heart Failure - blood; Heart Failure - physiopathology; Humans; Hypertension; Ischemia; Male; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Peptides; Peptides - blood; Public Health; Quality of Life; Quality of Life Research; Questionnaires; Regression analysis; Sociology; Surveys and Questionnaires
• ISSN: 0962-9343; 1573-2649
• DOI: 10.1007/s11136-011-9932-5

Purpose Assessment of circulating levels of collagenderived peptides has been proposed as a useful tool to monitor indirectly myocardial collagen metabolism in chronic heart failure (CHF) patients. The potential link between circulating concentrations of collagen metabolism biomarkers and health-related quality of life (HRQOL) has not been adequately evaluated. With the present study, we investigated the association between serum levels of collagen-derived peptides and HRQOL. Methods We studied 280 consecutive outpatients (of mean age 67 ± 10 years, 180 men) with CHF. Serum concentrations of carboxy-terminal telopeptide of collagen type I (CITP)—a marker of collagen type I degradation—were measured in all patients both at baseline and during a period of 6 months follow-up. HRQOL was assessed by Minnesota living with heart failure questionnaire (MLHFQ). Results CITP levels were significantly associated with MLHFQ scores both at baseline (r = 0.231, P < 0.001) and at 6 months follow-up (r = 0.145, P = 0.044). CITP levels remained significantly associated with MLHFQ score in multivariable linear regression analysis. Higher CITP levels were observed with higher MLHFQ scores (poor HRQOL) both at baseline (P = 0.001) and at 6 months (P = 0.041). Unadjusted analysis demonstrated a significant relationship between increasing CITP levels during 6 months follow-up and worsening HRQOL (r = 0.204, P = 0.001). The aforementioned correlation remained significant in multivariable linear regression analysis. Conclusion Our findings show that increased CITP levels are associated with poorer HRQOL in patients with CHF.These findings are consistent with a link between a pathophysiologic mechanism, i.e., collagen metabolism and patient self-assessed health status in CHF.